UK Parkinson's Disease Consortium - UKPDC
Bookmark and Share
Feed icon


Prof John Hardy

Prof John Hardy is the first UK winner of $3m Breakthrough Prize in Life Sciences

Professor John Hardy (UCL Institute of Neurology) has been awarded the $3 million Breakthrough Prize in Life Sciences for his pioneering research into the genetic causes of Alzheimer’s disease, other forms of dementia and Parkinson’s disease. More...

John Hardy, PhD, right, accepted the 2015 Robert A. Pritzker Prize from MJFF VP Brian Fiske, PhD, and Michael J. Fox on April 15.

John Hardy awarded 2015 Robert A. Pritzker Prize for Leadership in Parkinson's Research

One of the UK Parkinson's Disease Consortium Principal Investigators, Prof John Hardy, has been awarded the 2015 Robert A. Pritzker Prize for his leadership in Parkinson's genetics research. The award was presented by Michael J. Fox at a ceremony in New York on April 15. From the Michael J. Fox Foundation website: More...

Webcast - Prof Nicholas Wood - Advances in Genetic Understanding of Parkinson's Disease.

Video: Advances in Genetic Understanding of Parkinson's Disease

Webcast of the presentation entitled ‘Advances in Genetic Understanding of Parkinson's Disease’ given by Nicholas Wood (University College London, United Kingdom) presented at the Biochemical Society Hot Topic event, PINK1-Parkin Signalling in Parkinson’s Disease and Beyond, held in December 2014. More...

Pedigrees and I-FP-CIT SPECT scan images of the four families with GCH1 mutations involved in this study.

GCH1 gene and Parkinson's risk

A study published in Brain, led by researchers at UCL Institute of Neurology, has shown that genetic mutations which cause a decrease in dopamine production in the brain and lead to a form of childhood-onset Dystonia, also play a role in the development of Parkinson’s disease.

Leonard Wolfson Experimental Neurology Centre (LWENC)

The new Leonard Wolfson Experimental Neurology Centre (LWENC) has opened for clinical studies and trials


MRC Centre for Neuromuscular Diseases, UCL

Genetic and acquired neuromuscular diseases represent a major cause of mortality and morbidity in children and adults with a prevalence of more than 5% in the general population. Currently there is a large gap between major basic science discoveries and patient benefit in these important disorders. In order to reduce this gap we form the first truly multidisciplinary translational research centre into these disabling diseases. Our mission is to translate basic science findings into clinical trials and new treatments for children and adults with disabling neuromuscular diseases.

The MRC Centre for Neuromuscular Diseases is based at the UCL Institute of Neurology in collaboration with the UCL Institute of Child Health, other departments of UCL and at the University of Newcastle Upon Tyne. There is a very large adult and paediatric patient populations with neuromuscular diseases cared for at the co-located hospitals: The National Hospital for Neurology and Neurosurgery (NHNN), UCLH Foundation Trust; Great Ormond Street NHS Trust, and the Newcastle teaching hospitals.


Page last modified on 17 mar 11 16:04